The Prognostic and Clinical Value of Neutrophil-to-Lymphocyte Ratio (NLR) in Ovarian Cancer: A Systematic Review and Meta-analysis
NLR's Role in Ovarian Cancer: Review & Analysis
Abstract
Background: Ovarian cancer (OC) is a major gynecological malignancy with varying prognosis. The Neutrophil-to-Lymphocyte Ratio (NLR) has been proposed as a potential prognostic biomarker. This study aimed to evaluate the prognostic and clinical value of NLR in OC.
Methods: A systematic review and meta-analysis were performed following PRISMA guidelines, including studies that evaluated the association between NLR and survival outcomes in OC patients. Search was performed in PubMed, Embase, Web of Science, and Cochrane Library databases. Quality assessment was done using Newcastle-Ottawa Scale (NOS). Heterogeneity was assessed, and pooled hazard ratios (HRs) were calculated using fixed or random-effects models as appropriate.
Results: Twenty studies involving various ethnicities, ages, and sample sizes were included. A high NLR was found to be inversely correlated with overall survival (OS) (HR= 1.21, 95% CI 1.09-1.34, P<0.001) and progression-free survival (PFS) (HR=1.20, 95% CI 1.03-1.38, P<0.001). Stratified analyses showed a stronger association in Asian patients, studies with smaller sample sizes, younger patients, and higher NLR cutoff values.
Conclusions: The meta-analysis suggests a significant inverse association between NLR and survival outcomes in OC patients, emphasizing NLR's potential as a simple, cost-effective prognostic biomarker. However, substantial heterogeneity and influence of confounding factors underscore the need for further investigation.
References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. Ca-Cancer J Clin 2020; 70(1): 7-30.
2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Ca-Cancer J Clin 2021; 71(3): 209-49.
3. Cho KR, Shih I. Ovarian cancer. Annu Rev Pathol-Mech 2009; 4: 287-313.
4. Menon U, Karpinskyj C, Gentry-Maharaj A. Ovarian Cancer Prevention and Screening. Obstet Gynecol 2018; 131(5): 909-27.
5. Maccio A, Madeddu C. Inflammation and ovarian cancer. Cytokine 2012; 58(2): 133-47.
6. Ocana A, Nieto-Jimenez C, Pandiella A, Templeton AJ. Neutrophils in cancer: prognostic role and therapeutic strategies. Mol Cancer 2017; 16(1): 137.
7. Capone M, Giannarelli D, Mallardo D, Madonna G, Festino L, Grimaldi AM, et al. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. J Immunother Cancer 2018; 6(1): 74.
8. Cupp MA, Cariolou M, Tzoulaki I, Aune D, Evangelou E, Berlanga-Taylor AJ. Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies. Bmc Med 2020; 18(1): 360.
9. Gallego A, Mendiola M, Hernando B, Berjon A, Cadiz A, Chaves-Urbano B, et al. Prognostic markers of inflammation in endometrioid and clear cell ovarian cancer. Int J Gynecol Cancer 2022; 32(8): 1009-16.
10. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Bmj-Brit Med J 2021; 372: n71.
11. Lamba P, Sharma D, Sinnarkar VV. Polycystic Ovarian Syndrome Treated with Individualized Homeopathy: A Case Report. Altern Ther Health M 2022; 28(6): 60-4.
12. Zhou M, Li L, Wang X, Wang C, Wang D. Neutrophil-to-Lymphocyte Ratio and Platelet Count Predict Long-Term Outcome of Stage IIIC Epithelial Ovarian Cancer. Cell Physiol Biochem 2018; 46(1): 178-86.
13. Komura N, Mabuchi S, Yokoi E, Kozasa K, Kuroda H, Sasano T, et al. Comparison of clinical utility between neutrophil count and neutrophil-lymphocyte ratio in patients with ovarian cancer: a single institutional experience and a literature review. Int J Clin Oncol 2018; 23(1): 104-13.
14. Kim YJ, Lee I, Chung YS, Nam E, Kim S, Kim SW, et al. Pretreatment neutrophil-to-lymphocyte ratio and its dynamic change during neoadjuvant chemotherapy as poor prognostic factors in advanced ovarian cancer. Obstet Gynecol Sci 2018; 61(2): 227-34.
15. Li Z, Hong N, Robertson M, Wang C, Jiang G. Preoperative red cell distribution width and neutrophil-to-lymphocyte ratio predict survival in patients with epithelial ovarian cancer. Sci Rep-Uk 2017; 7: 43001.
16. Wang YQ, Jin C, Zheng HM, Zhou K, Shi BB, Zhang Q, et al. A novel prognostic inflammation score predicts outcomes in patients with ovarian cancer. Clin Chim Acta 2016; 456: 163-9.
17. Paik ES, Shim M, Choi HJ, Lee YY, Kim TJ, Choi CH, et al. Preoperative multiplication of neutrophil and monocyte counts as a prognostic factor in epithelial ovarian cancer. Cancer Biomark 2016; 17(4): 419-25.
18. Nakamura K, Nagasaka T, Nishida T, Haruma T, Ogawa C, Kusumoto T, et al. Neutrophil to lymphocyte ratio in the pre-treatment phase of final-line chemotherapy predicts the outcome of patients with recurrent ovarian cancer. Oncol Lett 2016; 11(6): 3975-81.
19. Miao Y, Yan Q, Li S, Li B, Feng Y. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy. Cancer Biomark 2016; 17(1): 33-40.
20. Kim HS, Choi HY, Lee M, Suh DH, Kim K, No JH, et al. Systemic Inflammatory Response Markers and CA-125 Levels in Ovarian Clear Cell Carcinoma: A Two Center Cohort Study. Cancer Res Treat 2016; 48(1): 250-8.
21. Feng Z, Wen H, Bi R, Ju X, Chen X, Yang W, et al. Preoperative Neutrophil-to-Lymphocyte Ratio as a Predictive and Prognostic Factor for High-Grade Serous Ovarian Cancer. Plos One 2016; 11(5): e156101.
22. Eo WK, Chang HJ, Kwon SH, Koh SB, Kim YO, Ji YI, et al. The Lymphocyte-Monocyte Ratio Predicts Patient Survival and Aggressiveness of Ovarian Cancer. J Cancer 2016; 7(3): 289-96.
23. Badora-Rybicka A, Nowara E, Starzyczny-Slota D. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio before chemotherapy as potential prognostic factors in patients with newly diagnosed epithelial ovarian cancer. Esmo Open 2016; 1(2): e39.
24. Zhang WW, Liu KJ, Hu GL, Liang WJ. Preoperative platelet/lymphocyte ratio is a superior prognostic factor compared to other systemic inflammatory response markers in ovarian cancer patients. Tumour Biol 2015; 36(11): 8831-7.
25. Wang Y, Liu P, Xu Y, Zhang W, Tong L, Guo Z, et al. Preoperative neutrophil-to-lymphocyte ratio predicts response to first-line platinum-based chemotherapy and prognosis in serous ovarian cancer. Cancer Chemoth Pharm 2015; 75(2): 255-62.
26. Williams KA, Labidi-Galy SI, Terry KL, Vitonis AF, Welch WR, Goodman A, et al. Prognostic significance and predictors of the neutrophil-to-lymphocyte ratio in ovarian cancer. Gynecol Oncol 2014; 132(3): 542-50.
27. Kokcu A, Kurtoglu E, Celik H, Tosun M, Malatyalioglu E, Ozdemir AZ. May the platelet to lymphocyte ratio be a prognostic factor for epithelial ovarian cancer? Asian Pac J Cancer Prev 2014; 15(22): 9781-4.
28. Raungkaewmanee S, Tangjitgamol S, Manusirivithaya S, Srijaipracharoen S, Thavaramara T. Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. J Gynecol Oncol 2012; 23(4): 265-73.
29. Thavaramara T, Phaloprakarn C, Tangjitgamol S, Manusirivithaya S. Role of neutrophil to lymphocyte ratio as a prognostic indicator for epithelial ovarian cancer. J Med Assoc Thai 2011; 94(7): 871-7.
30. Asher V, Lee J, Innamaa A, Bali A. Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer. Clin Transl Oncol 2011; 13(7): 499-503.
31. Cho H, Hur HW, Kim SW, Kim SH, Kim JH, Kim YT, et al. Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immun 2009; 58(1): 15-23.
32. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420(6917): 860-7.
33. Singh R, Mishra MK, Aggarwal H. Inflammation, Immunity, and Cancer. Mediat Inflamm 2017; 2017: 6027305.
34. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007; 117(5): 1175-83.
35. Grivennikov SI, Karin M. Inflammation and oncogenesis: a vicious connection. Curr Opin Genet Dev 2010; 20(1): 65-71.
36. Shalapour S, Karin M. Immunity, inflammation, and cancer: an eternal fight between good and evil. J Clin Invest 2015; 125(9): 3347-55.
Copyright (c) 2023 Zihan Zhang, Jinghe Lang
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.